















- [19] Kumar R, Singla V, Kacharya Sk. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients. *Trop Gastroenterol*. 2008; 29:136-47.
- [20] Assemie MA, Alene M, Ketema DB, Mulatu S. Treatment failure and associated factors among first-line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis. *Glob Health Res Policy*. 2019; 4:32.
- [21] Hunt GM, Dokubo EK, Takuva S, de Oliveira T, Ledwaba J, Dube N, et al. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. *J Antimicrob Chemother*. 2017; 72: 3141-3148.
- [22] Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondo P, Wellington M, et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. *J Antimicrob Chemother*. 2016; 71:2918-27.
- [23] Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. *Plos one*. 2019; 14: e0211344.
- [24] Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. *Lancet Infect Dis*. 2010; 10:155-66.
- [25] Bain LE, Nkoke C, Noubiap JJN. UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are not realistic: comment on “Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades”. *BMJ Glob Health*. 2017; 2: e000227.
- [26] Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. International Study of Patients with HIV on Rifampicin ING study group. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected with Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. *Clin Infect Dis*. 2020; 70: 549-556.
- [27] Vadlapatla RK, Patel M, Paturi DK, Pal D, Mitra AK. Clinically relevant drug-drug interactions between antiretrovirals and antifungals. *Expert Opin Drug Metab Toxicol*. 2014; 10:561-80.
- [28] Tivicay (Dolutegravir) Package Insert. Research Triangle Park, NC: GlaxoSmithKline; 2013.